NGM Biopharmaceuticals (United States)
- World rank, all time
- #14,659 of 42,892
- Rank in United States
- #3,202 of 8,685
- Research works
- 216 ▲ 31% vs 2013–17
- Citations
- 15k 67.9 per fractional work
- Top-10% rate
- 20.7% record average 16.5%
- Open access
- 37% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 18.1×. Every wedge is a field page.
- Immunology and Microbiology 18.1×
- Biochemistry, Genetics and Molecular Biology 3.0×
- Medicine 2.9×
- Pharmacology, Toxicology and Pharmaceutics 2.1×
- Nursing 1.4×
- Health Professions 0.6×
- Economics, Econometrics and Finance 0.5×
- Chemistry 0.4×
- Agricultural and Biological Sciences 0.3×
- Environmental Science 0.2×
- Neuroscience 0.2×
- Engineering 0.1×
- Materials Science 0.1×
- Computer Science 0.0×
Who are the top researchers at NGM Biopharmaceuticals (United States)?
Ranked on the composite score, Julie M. Roda lead among researchers whose main affiliation is NGM Biopharmaceuticals (United States).
- 1 Julie M. Roda United States · #1,551,679 worldwide 22 citations · 16 works
Which keywords describe research at NGM Biopharmaceuticals (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Inflammation, Tumor Microenvironment, Cancer, Immunity, Cancer Therapy, Immunotherapy, Prognostic Factors and Natural Killer Cells.
- Acute Myeloid Leukemia
- Mutation
- Innate Immunity
- Activation
- Immune Checkpoint Blockade
- Oxidative Stress
- PET Imaging
- Angiogenesis
- NK Cell Recognition
- Immunotherapy
- Immunity
- Tumor Microenvironment
- Inflammation
- Cancer
- Cancer Therapy
- Prognostic Factors
- Natural Killer Cells
- Cancer Immunotherapy
- Immune Response
- Metabolism
- PD-1 and PD-L1
- Epidemiology
- Macrophage
- AML
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 24 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 24 words, with their numbers
- Inflammation3▲ 6.1×15 topics
- Tumor Microenvironment3▲ 25×6 topics
- Cancer2▲ 7.5×11 topics
- Immunity2▲ 22×4 topics
- Cancer Therapy2▲ 14×6 topics
- Immunotherapy2▲ 11×9 topics
- Prognostic Factors2▲ 16×5 topics
- NK Cell Recognition2▲ 98×1 topic
- Natural Killer Cells2▲ 98×1 topic
- Angiogenesis2▲ 19×6 topics
- Cancer Immunotherapy2▲ 38×3 topics
- PET Imaging2▲ 34×3 topics
- Immune Response1▲ 10×5 topics
- Oxidative Stress1▲ 3.4×12 topics
- Metabolism1▲ 10.0×4 topics
- Immune Checkpoint Blockade1▲ 44×1 topic
- PD-1 and PD-L11▲ 44×1 topic
- Activation1▲ 71×1 topic
- Epidemiology1◆ 1.11×10 topics
- Innate Immunity1▲ 13×3 topics
- Macrophage1▲ 59×1 topic
- Mutation1▲ 23×5 topics
- AML1▲ 81×1 topic
- Acute Myeloid Leukemia1▲ 81×1 topic
Which research topics does NGM Biopharmaceuticals (United States) publish most on?
By volume in 2022–2025: Immune Cell Function and Interaction, Cancer Immunotherapy and Biomarkers, Immune cells in cancer and Acute Myeloid Leukemia Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Immune Cell Function and Interaction Immunology 2 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 3 Immune cells in cancer Immunology 1 works
- 4 Acute Myeloid Leukemia Research Hematology 1 works
- 5 Immunotherapy and Immune Responses Immunology 1 works
- 6 Peptidase Inhibition and Analysis Oncology 1 works
- 7 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 8 Melanoma and MAPK Pathways Molecular Biology 1 works
- 9 Protein Degradation and Inhibitors Molecular Biology 0 works
- 10 Cytokine Signaling Pathways and Interactions Oncology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has NGM Biopharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 31% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in South San Francisco
- Sunesis (United States)
- Exelixis (United States)
- Kaiser Permanente South San Francisco Medical Center
- Cytokinetics (United States)
- Portola Pharmaceuticals (United States)
- Rapt Therapeutics (United States)
- Atara Biotherapeutics (United States)
- Fluidigm (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.